Charité Biomedical Fund
VC Fund
Charité Biomedical Fund is a VC fund focused on Biotechnology and Software. Charité Biomedical Fund
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Charité Biomedical Fund invests in
Stages Charité Biomedical Fund invests in
Countries Charité Biomedical Fund invests in
Investment Focus
Industry
- Biotechnology 2 (100%)
- Software 1 (50%)
- Life Science 1 (50%)
- Medical Device 1 (50%)
- Enterprise Software 1 (50%)
Stage
- Series A 1 (50%)
- Series B 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Labforward supports laboratory teams on their quest for groundbreaking discoveries and delivering innovative high-quality products. With digital tools for laboratories, it increases productivity and improves efficiency in laboratories. The company's products include the user-friendly electronic laboratory notebook (ELN) Labfolder and theInternet-of-Things (IoT) platform Laboperator. The digital connectivity of laboratories and innovative data management is a focus topic in industry and research. In a fragmented landscape of high-tech equipment and specialized software, Labforward links data silos and helps to eliminate costly and error-prone data transfers. Based on this horizontal connectivity, the software Laboperator enables the remote control and monitoring of laboratory equipment, the integration of LIMS systems, databases and special software as well as the automation of workflows. The Labfolder data platform aggregates both automatically recorded and manually added data and enables the review, sharing, retrieval and validation of data by means of a collaborative ELN. Whether life sciences, chemical synthesis, analytics, quality control or research and development: no matter how specific the field or task of a laboratory may be, the way it works and the requirements for data management have a common core. Labforward focuses on this core. | $8.1M / Series B / Sep 01, 2015 | ||
| Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes.LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally. | Series A / Oct 12, 2011 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Charité Biomedical Fund invest in?
Charité Biomedical Fund invests primarily in Biotechnology, Software and Life Science startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Charité Biomedical Fund last invest?
The most recent investment recorded for Charité Biomedical Fund closed in Sep 2015. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
